Search Results - BioPharma

36 Results

Sort By:

RESEARCH TOOL: Biotinylated bioluminescent probe (YuLu) for the detection of luciferase

The global preclinical imaging market is estimated to reach 910 million in the US alone by 2021, including utilizing bioluminescent probes to study biological processes in vitro and in vivo in real time, image cancer cells, monitor gene delivery and adoptively transferred cells and track pathogen clearance, detect apoptosis and research signal transduction....

Published: 5/2/2023 | Inventor(s): Ann-Marie Broome (Deceased), Yu-Lin Jiang

Keywords(s):

Category(s): BioPharma

Electrically Conductive Nanomaterials Reinforced Cardiac Microtissues

Technology: Progenitor cells provide strong regenerative ability, but are limited by their immature phenotype and inability to generate functional tissues equivalent to adult cardiomyocytes. This technology provides a novel approach to successfully regenerate functional cardiomyocytes from progenitor cells. The strategy involves providing a physiologically-relevant...

Published: 3/22/2023 | Inventor(s): Donald Menick, Ying Mei, Tan Yu, Dylan Richards, Bozhi Tian

Keywords(s):

Category(s): BioPharma

Pseudo-Diaphragmatic Expansion Perfusion & Cryopreservation of Intact Viable Tissues

Researchers at MUSC have developed a rapid and reproducible method for the cryopreservation of a variety of tissues, such that when thawed are comparable to freshly resected tissues. To date, analysis has been completed on lung tissue from patients undergoing lobectomy or transplant and prostate tissue. This method involves the pseudo-diaphragmatic...

Published: 3/23/2023 | Inventor(s): John Baatz, Demetri d. Spyropoulos

Keywords(s):

Category(s): BioPharma

G9a inhibition decreases stress-induced escalation of alcohol drinking

Technology: Inventors at MUSC have identified that NAc (nucleus accumbens) G9a is required for stress-regulated drinking in both ethanol-dependent and non-dependent animals. Importantly they discovered that treating mice with UNC0642 (an inhibitor of G9a) in a stressinduced ethanol drinking assay (Figure. 1A) showed significant reduction in ethanol...

Published: 8/23/2023 | Inventor(s): Ethan Anderson, Christopher Cowan

Keywords(s):

Category(s): BioPharma

CaMKK-β as a target for prevention of noise- and aminoglycoside-induced hearing loss

Compositions and Methods for Attenuation of Hearing Loss Technology: Researchers at MUSC have developed a biopharmaceutical therapy that reduces the expression of specific proteins associated with both noise and chemically induced hearing loss. The invention provides a gene therapy and therapeutic target for prevention of acquired hearing loss. Previous...

Published: 3/23/2023 | Inventor(s): Su-Hua Sha

Keywords(s):

Category(s): BioPharma

Monobody R15 targets the nucleotide free state of RAS to block oncogenic signaling and transformation

Technology: Researchers at MUSC and NYU Langone Medical Center have identified a synthetic protein (R15) that selectively binds to the nucleotide-free state of the RAS proto-oncogene (apoRAS) and is the first experimental tool to selectively inhibit the signaling and oncogenic activity of selected oncogenic RAS mutants (Figure 1). The synthetic protein...

Published: 3/23/2023 | Inventor(s): John O'Bryan, Shohei Koide, Akiko Koide

Keywords(s):

Category(s): BioPharma

Recombinant fusion proteins and complement inhibitors targeting P-selectin, and therapeutic and diagnostic application

Technology: Inventors at MUSC have designed fusion proteins to treat inflammatory and other related pathologies by binding p-selectin (PSel) and modulating complement. Although targeting complement has shown great promise in treating numerous pathologies which has also led to the approval of multiple drugs (e.g. eculizumab, Berinert, Cinryze), targeting...

Published: 7/22/2023 | Inventor(s): Stephen Tomlinson, Ali Alawieh, Pablo Engel

Keywords(s):

Category(s): BioPharma

Advancements of 599 peptide carrier design through stereochemical and/or amino acid modifications

Technology: Researchers at MUSC have developed a cell-penetrating peptide (CPP) specifically designed to overcome challenges associated with small interfering RNA (siRNA)-drug delivery for cancer treatment. Investigators previously generated the 599 peptide that silenced the CIP2A oncogene and suppressed tumor growth in vivo (Figure 1). Figure...

Published: 3/22/2023 | Inventor(s): Andrew Jakymiw, Charles Holjencin

Keywords(s):

Category(s): BioPharma

Click Chemistry Probes for Specific Targeting of Sialic Acid Tumor Antigens

Technology: Researchers at MUSC have identified methods for selectively modifying linked sialic acid or polysialic acid with bioorthagonal reaction schemes having applications broad applications in drug delivery. This is achieved by exposing a 2,3 linked sialic acid and/or a 2,8 linked polysialic acid to condensing reagents under suitable reaction conditions....

Published: 3/15/2023 | Inventor(s): Richard Drake, Xiaowei (Vivian) Lu

Keywords(s):

Category(s): BioPharma

Blocking GARP (LRRC32) cleavage and Its Application in Immunotherapy

Technology: Researchers at MUSC have developed a method and peptide composition (the “T250 peptide”) for treating cancer by inhibiting Glycoprotein-A Repetitions Predominant Protein (GARP) cleavage and thus impeding the activation of Transforming Growth Factor-Beta (TGF-β) – a growth factor that suppresses T-cell mediated anti-cancer...

Published: 3/23/2023 | Inventor(s): Zihai Li

Keywords(s):

Category(s): BioPharma

1 2 3 4